HomeAI · summaries
Storia in 5 fonti
Jury Hits Takeda With $885 Million Antitrust Verdict - Takeda Pharmaceutical Co (NYSE:TAK)
Takeda faces nearly $885 million jury verdict in AMITIZA antitrust case and plans post-trial motions and appeal.
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
asia.nikkei.com
Takeda found liable over antitrust plot to delay generic constipation drug
Japanese drugmaker was accused by US pharmacies, retailers of 'pay-for-delay' scheme
- ·
morningstar.com
Attorneys at Hagens Berman Announce $474M Win in Amitiza Jury Trial Against Takeda
Attorneys at Hagens Berman Announce $474M Win in Amitiza Jury Trial Against Takeda
